Synaptogenix announces agreement with Cleveland Clinic for Bryostatin-1 trial

Synaptogenix announced that it entered into an agreement with Cleveland Clinic to conduct a phase 1 trial of Bryostatin-1 in multiple sclerosis, or MS. Cleveland Clinic will manage the clinical trial’s implementation, including an Investigational New Drug, or IND, submission to the FDA and patient enrollment. Alan Tuchman, CEO of Synaptogenix, said, “With approximately $35.8 million in cash as of March 31, 2023, and a relatively low cash burn rate, Synaptogenix is well-funded with ample resources to continue its development of Bryostatin-1 for MS in collaboration with Cleveland Clinic, including initiation of the upcoming trial anticipated to commence in the fourth quarter of 2023. As we move forward with this study, we will continue to pursue other potential business endeavors including the identification of other assets for clinical development.” Bryostatin-1 is a small molecule that works by activating protein kinase C, an enzyme required for maintaining synapse health, and involved in learning and memory. The therapy may also influence the immune system toward anti-inflammatory efficacy. Preclinical studies have already demonstrated Bryostatin’s potential to address cognitive impairment in other neurodegenerative disorders such as Alzheimer’s disease, traumatic brain injury, and Fragile X syndrome. MS may represent a new indication to ameliorate cognitive impairment.